vs
Certara, Inc.（CERT）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Certara, Inc.的2.0倍（$207.3M vs $103.6M），Certara, Inc.净利率更高（-5.7% vs -62.0%，领先56.3%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 3.3%），Certara, Inc.自由现金流更多（$27.8M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 3.6%）
Certara是全球领先的生物制药软件及咨询服务提供商，专注于建模模拟、监管科学领域的解决方案，服务药企、生物技术企业及医疗相关方，覆盖药物研发全周期，助力加快新疗法上市，降低研发风险与综合成本。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CERT vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $103.6M | $207.3M |
| 净利润 | $-5.9M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 0.8% | -54.7% |
| 净利率 | -5.7% | -62.0% |
| 营收同比 | 3.3% | 25.9% |
| 净利润同比 | -189.6% | 3.5% |
| 每股收益（稀释后） | $-0.04 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $103.6M | $207.3M | ||
| Q3 25 | $104.6M | $159.9M | ||
| Q2 25 | $104.6M | $166.5M | ||
| Q1 25 | $106.0M | $139.3M | ||
| Q4 24 | $100.4M | $164.6M | ||
| Q3 24 | $94.8M | $139.5M | ||
| Q2 24 | $93.3M | $147.0M | ||
| Q1 24 | $96.7M | $108.8M |
| Q4 25 | $-5.9M | $-128.6M | ||
| Q3 25 | $1.5M | $-180.4M | ||
| Q2 25 | $-2.0M | $-115.0M | ||
| Q1 25 | $4.7M | $-151.1M | ||
| Q4 24 | $6.6M | $-133.2M | ||
| Q3 24 | $-1.4M | $-133.5M | ||
| Q2 24 | $-12.6M | $-131.6M | ||
| Q1 24 | $-4.7M | $-170.7M |
| Q4 25 | 0.8% | -54.7% | ||
| Q3 25 | 2.9% | -106.9% | ||
| Q2 25 | 9.1% | -64.8% | ||
| Q1 25 | 7.2% | -102.6% | ||
| Q4 24 | 6.0% | -74.3% | ||
| Q3 24 | 2.7% | -94.6% | ||
| Q2 24 | -9.7% | -79.1% | ||
| Q1 24 | -1.3% | -151.9% |
| Q4 25 | -5.7% | -62.0% | ||
| Q3 25 | 1.5% | -112.8% | ||
| Q2 25 | -1.9% | -69.0% | ||
| Q1 25 | 4.5% | -108.5% | ||
| Q4 24 | 6.6% | -80.9% | ||
| Q3 24 | -1.4% | -95.7% | ||
| Q2 24 | -13.5% | -89.5% | ||
| Q1 24 | -4.8% | -156.8% |
| Q4 25 | $-0.04 | $-1.28 | ||
| Q3 25 | $0.01 | $-1.81 | ||
| Q2 25 | $-0.01 | $-1.17 | ||
| Q1 25 | $0.03 | $-1.57 | ||
| Q4 24 | $0.04 | $-1.34 | ||
| Q3 24 | $-0.01 | $-1.40 | ||
| Q2 24 | $-0.08 | $-1.52 | ||
| Q1 24 | $-0.03 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $189.4M | $421.0M |
| 总债务越低越好 | $293.1M | — |
| 股东权益账面价值 | $1.1B | $-80.0M |
| 总资产 | $1.6B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
| Q4 25 | $189.4M | $421.0M | ||
| Q3 25 | $172.7M | $202.5M | ||
| Q2 25 | $162.3M | $176.3M | ||
| Q1 25 | $179.1M | $127.1M | ||
| Q4 24 | $179.2M | $174.0M | ||
| Q3 24 | $233.0M | $150.6M | ||
| Q2 24 | $224.6M | $480.7M | ||
| Q1 24 | $224.8M | $112.3M |
| Q4 25 | $293.1M | — | ||
| Q3 25 | $293.5M | — | ||
| Q2 25 | $294.2M | — | ||
| Q1 25 | $294.8M | — | ||
| Q4 24 | $295.4M | — | ||
| Q3 24 | $296.1M | — | ||
| Q2 24 | $296.7M | — | ||
| Q1 24 | $290.8M | — |
| Q4 25 | $1.1B | $-80.0M | ||
| Q3 25 | $1.1B | $9.2M | ||
| Q2 25 | $1.1B | $151.3M | ||
| Q1 25 | $1.1B | $144.2M | ||
| Q4 24 | $1.1B | $255.0M | ||
| Q3 24 | $1.1B | $346.8M | ||
| Q2 24 | $1.0B | $432.4M | ||
| Q1 24 | $1.1B | $140.3M |
| Q4 25 | $1.6B | $1.5B | ||
| Q3 25 | $1.5B | $1.2B | ||
| Q2 25 | $1.5B | $1.3B | ||
| Q1 25 | $1.6B | $1.3B | ||
| Q4 24 | $1.6B | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.5B | $1.3B |
| Q4 25 | 0.28× | — | ||
| Q3 25 | 0.28× | — | ||
| Q2 25 | 0.27× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.28× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | 0.28× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $28.8M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $27.8M | $-100.8M |
| 自由现金流率自由现金流/营收 | 26.8% | -48.6% |
| 资本支出强度资本支出/营收 | 1.0% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $94.4M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $28.8M | $-99.8M | ||
| Q3 25 | $32.3M | $-91.4M | ||
| Q2 25 | $17.8M | $-108.3M | ||
| Q1 25 | $17.4M | $-166.5M | ||
| Q4 24 | $49.4M | $-79.3M | ||
| Q3 24 | $17.0M | $-67.0M | ||
| Q2 24 | $9.8M | $-77.0M | ||
| Q1 24 | $4.3M | $-190.7M |
| Q4 25 | $27.8M | $-100.8M | ||
| Q3 25 | $32.1M | $-92.7M | ||
| Q2 25 | $17.8M | $-110.7M | ||
| Q1 25 | $16.8M | $-167.8M | ||
| Q4 24 | $49.0M | $-79.5M | ||
| Q3 24 | $16.8M | $-68.6M | ||
| Q2 24 | $9.4M | $-79.0M | ||
| Q1 24 | $3.7M | $-193.9M |
| Q4 25 | 26.8% | -48.6% | ||
| Q3 25 | 30.7% | -58.0% | ||
| Q2 25 | 17.0% | -66.5% | ||
| Q1 25 | 15.8% | -120.5% | ||
| Q4 24 | 48.8% | -48.3% | ||
| Q3 24 | 17.7% | -49.2% | ||
| Q2 24 | 10.1% | -53.7% | ||
| Q1 24 | 3.8% | -178.2% |
| Q4 25 | 1.0% | 0.5% | ||
| Q3 25 | 0.2% | 0.8% | ||
| Q2 25 | 0.1% | 1.5% | ||
| Q1 25 | 0.6% | 1.0% | ||
| Q4 24 | 0.4% | 0.1% | ||
| Q3 24 | 0.2% | 1.2% | ||
| Q2 24 | 0.5% | 1.4% | ||
| Q1 24 | 0.6% | 3.0% |
| Q4 25 | — | — | ||
| Q3 25 | 21.19× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.66× | — | ||
| Q4 24 | 7.51× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CERT
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
